Home › Compare › TKUMF vs ABBV
TKUMF yields 5.46% · ABBV yields 3.06%● Live data
📍 TKUMF pulled ahead of the other in Year 1
Combined, TKUMF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TKUMF + ABBV for your $10,000?
Takuma Co., Ltd. engages in the design, construction, and superintendence of various boilers, plant machineries, pollution prevention and environmental equipment plants, heating and cooling equipment, and feed water/drainage sanitation equipment and facilities in Japan and internationally. It operates through four segments: Domestic Environment and Energy Business, Overseas Environment and Energy Business, Package Boiler Business, and Equipment and System Business. The Domestic Environment and Energy Business segment operates general waste treatment, industrial waste treatment, waste recycling, wastewater treatment, sludge combustion, and biomass power plants. The Overseas Environment and Energy Business segment operates waste combusting and biomass power plants. The Package Boiler Business segment offers compact through-flow boilers and vacuum water heating systems. The Equipment and System Business segment provides construction equipment, and equipment for the semiconductor industry and cleaning systems. The company was formerly known as Takuma Boiler Manufacturing Co., Ltd. and changed its name to Takuma Co., Ltd. in 1972. Takuma Co., Ltd. was incorporated in 1938 and is headquartered in Amagasaki, Japan.
Full TKUMF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.